Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389 - sprookjes - yvandenbroek - TriplyDB

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

http://www.wikidata.org/entity/Q28277346

about

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase Eribulin in Cancer Treatment Scrutinizing the scaffolds of marine biosynthetics from different source organisms: Gram-negative cultured bacterial products enter center stage Beyond taxanes: the next generation of microtubule-targeting agents Trypanocidal activity of marine natural products Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy Systematic review of ixabepilone for treating metastatic breast cancer.Iron complexation to oxygen rich marine natural products: a computational study.Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.Bio-inspired synthesis and biological evaluation of a colchicine-related compound library Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models ET743: Chemical analysis of the sea squirt Ecteinascidia turbinata ecosystem.Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.Eribulin mesylate in the treatment of metastatic breast cancer Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane SD118-xanthocillin X (1), a novel marine agent extracted from Penicillium commune, induces autophagy through the inhibition of the MEK/ERK pathway.Eribulin mesylate in patients with refractory cancers: a Phase I study.Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium.Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life.Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.Mitochondria-targeted Triphenylamine Derivatives Activatable by Two-Photon Excitation for Triggering and Imaging Cell Apoptosis Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy.Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer.Potential clinical applications of halichondrins in breast cancer and other neoplasms.Novel anti-tubulin cytotoxic agents for breast cancer.Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition.Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.Eribulin -- a review of preclinical and clinical studies.Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma.Eribulin mesylate for the treatment of breast cancer.The medicinal potential of promising marine macrolides with anticancer activity.

P2860

Q24657514-E3489EF3-C287-4556-9EE0-DC2D33035CAA Q26799328-D6B2BA94-0C05-4C8E-8820-67F284D455D0 Q26860194-3F5F6BA0-94AA-43BE-81C2-BE5E1BADA77A Q26865369-EBE60E28-B991-4D50-8C00-6F1F2AF21882 Q27008593-071224A5-6568-47CF-B2E6-D184C43BAB5B Q28074125-895CF0E5-C7FC-4EC1-95A3-1EF951FBD378 Q28078116-9C85A567-079C-4305-8AED-21686612EC44 Q28088354-1D1DBF94-761B-4C62-8720-81306EA1B6F9 Q30248627-5A54C47C-FFA5-4469-BBEA-21DB15D59F07 Q33635487-4380CD1F-736D-4E47-987E-84628C639368 Q34062522-C426BDC3-E5F2-4B8C-9EDC-F5D431A2B29C Q34250018-AE1F2A58-035D-4E51-9B90-2EB48DB97DF0 Q34406761-41AF7943-C543-45A1-9543-CF5A4BF584A2 Q34430739-92FC29BC-5B63-4C88-9342-E981A91C39BE Q34566870-980C60D0-8F10-41D1-A164-5F20E7072D01 Q34687059-A6C0BED2-D351-447F-8069-D6152B598A76 Q34964991-0440CB37-12AB-4CF7-BF93-0D848F7599B0 Q35699382-CFADB22A-E9DE-443E-BED0-A8C96421B1D8 Q35721526-22BB8950-575F-4B09-B470-1388225B7C57 Q36096714-85A22D0E-5F68-4BB0-9C0A-E57EACB22251 Q36205403-D267DE8E-DAE0-46C6-A040-DC38BC3F3C05 Q36411072-ECCAF1B7-D71F-4CB8-B5DE-2E397559778E Q36443858-0EB5A063-EEC1-4F29-93A3-7387549C0F9E Q36484243-23F647B3-A425-43C0-A2EB-FCB561B24E18 Q36597347-02F92164-022D-4438-93D2-0287BE81E66E Q36657146-BB7AA88C-2F24-484F-B776-F19D26C23177 Q36742259-3F6DEFD0-0B6E-4311-BD37-851EAAF56572 Q36922483-E253EA2C-63A3-4A9E-BFB0-3D69B911A2E3 Q37052387-1AFEB1B4-1F1C-4EF8-AF58-64D51327124B Q37067999-5A499609-31F7-47F6-821D-3F83F6D4212B Q37356090-CBF35278-BA9E-4F10-95E2-B1D6BAEB721C Q37356164-4162BA84-26FA-457B-9252-7C5145A760E4 Q37385373-B7F5C172-D802-42FB-A022-9C7B1C0DA5B7 Q37419295-4E69A050-B012-420F-A195-30F21205AAA9 Q37626786-497F31BF-D596-436D-9AA7-9505DA1EAA85 Q37637936-303152FF-5B13-404C-963C-50E41DE1CBDD Q37699295-113F3189-5E14-43E6-8FAB-4B9535172F1D Q37722656-CC42C741-93EE-46E4-8C73-EDED2C13DFF5 Q37745070-4B3C1A1D-DE0B-4621-AAB6-C4184DA276F5 Q37837738-0E15539F-1751-4EBF-A194-3D47530ACB77

P2860

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

http://www.wikidata.org/entity/Q28277346

description

2004 nî lūn-bûn

@nan

2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Induction of morphological and ...... acrocyclic ketone analog E7389

@ast

Induction of morphological and ...... acrocyclic ketone analog E7389

@en

Induction of morphological and ...... acrocyclic ketone analog E7389

@nl

type

label

Induction of morphological and ...... acrocyclic ketone analog E7389

@ast

Induction of morphological and ...... acrocyclic ketone analog E7389

@en

Induction of morphological and ...... acrocyclic ketone analog E7389

@nl

prefLabel

Induction of morphological and ...... acrocyclic ketone analog E7389

@ast

Induction of morphological and ...... acrocyclic ketone analog E7389

@en

Induction of morphological and ...... acrocyclic ketone analog E7389

@nl

P1433

Q28277346-63C141B4-7BFD-48A9-8A09-5675A6825AD6

P1476

Q28277346-EF47BFB5-2861-46E0-BD1A-00B9AD46CBB6

P2093

Q28277346-0BB05812-5E44-42C1-A093-0F123A7EBCE6

Q28277346-0F14FF1F-88D0-4E50-BE8A-660841F2B9B3

Q28277346-1ADFBC6B-5BC2-42F3-A1F8-1CE30F332995

Q28277346-2644E735-414A-4AA0-BAF1-809D3B964627

Q28277346-5D330B55-D6E9-4A06-92BF-805CCDD1A663

Q28277346-7779BAE3-7C1A-4631-9184-E34C81890052

Q28277346-9EF251A1-7463-4924-B540-69BFAE75B4C4

Q28277346-ACC23FE8-01FB-4BAD-9EAC-E15CA943E357

Q28277346-FCA77FE6-15BB-4392-8DF1-005313ADA32B

P304

Q28277346-86885C81-9B70-4B01-87DE-CD2633309E42

P31

Q28277346-B508CD61-6F3C-4577-854A-B46F40CCE4F5

P3181

Q28277346-9FC75B40-E9B8-43C7-BC7C-D2977F53FE9B

P356

Q28277346-DB7DD867-1FCE-4364-9C1E-CE4FF89778AB

P407

Q28277346-440F5F0F-3EAA-4049-8859-E3B1098C05DD

P433

Q28277346-9FC351D5-EFE7-4923-BEB2-0742EF079033

P478

Q28277346-6F255E5D-F254-4F29-8755-81553821220B

P577

Q28277346-D98BEFF4-BAD9-401E-A1C9-69F4ABD06425

P698

Q28277346-446FD4C4-9861-4E68-8018-2E415DEAA809

P3181

P356

0008-5472.CAN-04-1169

P1433

Cancer Research

P1476

Induction of morphological and ...... acrocyclic ketone analog E7389

@en

P2093

Bruce A Littlefield

http://www.w3.org/2001/XMLSchema#string

Diana Liu

http://www.w3.org/2001/XMLSchema#string

Galina Kuznetsov

http://www.w3.org/2001/XMLSchema#string

Hongsheng Cheng

http://www.w3.org/2001/XMLSchema#string

Karen TenDyke

http://www.w3.org/2001/XMLSchema#string

Melvin J Yu

http://www.w3.org/2001/XMLSchema#string

Murray J Towle

http://www.w3.org/2001/XMLSchema#string

Takanori Kawamura

http://www.w3.org/2001/XMLSchema#string

Yoshito Kishi

http://www.w3.org/2001/XMLSchema#string

P304

5760-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

446119

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/0008-5472.CAN-04-1169

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P577

2004-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15313917

http://www.w3.org/2001/XMLSchema#string